Cytori Receives U.S. Patent Allowance for Key Commercial Products

(PresseBox) ( San Diego, )
Cytori Therapeutics, Inc. (NASDAQ: CYTX) received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application that protects key therapeutic methods for its breast and soft tissue reconstruction products. This patent will protect Cytori's existing and future products when sold in the U.S.

Cytori currently sells the Celution? 800/CRS System, which creates adipose tissue derived stem and regenerative cell enhanced autologous fat grafts, in many countries around the world. The allowed patent will protect alternative configurations of the Celution? 800/CRS System, including smaller versions with accelerated processing times tailored to procedures such as the treatment of stress urinary incontinence.

This patent allowance expands on the Company's previously issued core device patent, U.S. Patent No. 7,390,484, as well as the Company's previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cell enhanced fat grafts.

Cytori's intellectual property portfolio related to the devices, methods and uses of adipose-derived stem and regenerative cells includes ten U.S. and International patents and numerous applications worldwide.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

SOURCE: Cytori Therapeutics
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an